Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc

Prothena ( ($PRTA) ) has issued an update. On May 14, 2026, Prothena shareholders re-elected directors Shane M. Cooke and Dennis J. Selkoe to the b...

Prothena Shareholders Reaffirm Board, Auditor and Pay Policies

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA...

Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Prothena yesterday and set a price target of $13.00. Abrahams covers the Healthcare ...

Current Quarter	$-0.39	Next Quarter	$-0.38
Current Year	$0.18	Next Year	$-1.13
QoQ Growth	+2.6%	YoY Growth	-727.8%
3Y EPS CAGR	-22.4%	Target Price	$21.40
Consensus	Buy	Upside	+112.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRTA	$10.06	+2.34%	918.62K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRTA	$10.06	+2.3%	918.62K
3
4
5
6

PRTA

PRTA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Prothena Corporation plc Data in Excel

Get Prothena Corporation plc Data in Excel